Here, we reviewed evidence from the literature about the four multigene assays available in Italy and discussed about their optimal use and potential implementation in the evolving field of adjuvant treatment of ER+/HER2- breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.